INmune Bio Inc.

The momentum for this stock is not very good. INmune Bio Inc. is not a good growth stock. INmune Bio Inc. is a mediocre stock to choose.

Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that repr...

News

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Globe Newswire Boca Raton, Florida, Sept. 03, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the Company ), a clinical-stage inflammation and immunology company focused on developing treatments that...\n more…

PharmaCyte Biotech (OTCMKTS:PMCBD) & INmune Bio (NASDAQ:INMB) Financial Analysis

Zolmax INmune Bio (NASDAQ:INMB - Get Free Report) and PharmaCyte Biotech (OTCMKTS:PMCBD - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two...\n more…

Financial Analysis: PharmaCyte Biotech (OTCMKTS:PMCBD) vs. INmune Bio (NASDAQ:INMB)

Ticker Report INmune Bio (NASDAQ:INMB - Get Free Report) and PharmaCyte Biotech (OTCMKTS:PMCBD - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two...\n more…

INmune Bio (NASDAQ:INMB) Coverage Initiated by Analysts at Scotiabank

Ticker Report Scotiabank began coverage on shares of INmune Bio (NASDAQ:INMB - Get Free Report) in a research report issued on Thursday, Briefing.com reports. The firm set a "sector outperform" rating and a $22.00...\n more…

INmune Bio initiated with bullish view at Scotiabank

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Inmune Bio's Promising Pipeline and Strong Cash Position Merit a Buy Rating

TipRanks Financial Blog Joel Beatty, an analyst from Robert W. Baird, maintained the Buy rating on Inmune Bio (INMB - Research Report). The associated price target remains...\n more…